Psilocybin Therapy for Depression in Parkinson's Disease (NCT06455293)

Overview

This Phase 2 clinical trial investigates psilocybin as a novel treatment for depression in Parkinson's Disease (PD) patients. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients throughout the disease course. This trial represents a cutting-edge approach to addressing this unmet clinical need through psychedelic-assisted therapy.

Trial Details

Overview

This Phase 2 clinical trial investigates psilocybin as a novel treatment for depression in Parkinson's Disease (PD) patients. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients throughout the disease course. This trial represents a cutting-edge approach to addressing this unmet clinical need through psychedelic-assisted therapy.

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06455293 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | To be confirmed |
| Collaborators | To be confirmed |
| Intervention | Psilocybin |
| Purpose | Treatment of depression in PD |
| Study Type | Interventional |
| Estimated Enrollment | 40-60 participants |
| Study Design | Randomized, double-blind, placebo-controlled |

Mechanism of Action

Psilocybin exerts its therapeutic effects through multiple interconnected mechanisms:

5-HT2A Receptor Agonism

Psilocybin is a prodrug that is metabolized to psilocin, its active form. Psilocin acts as a partial agonist at serotonin 5-HT2A receptors, which are densely distributed in the prefrontal cortex and other brain regions involved in mood regulation. This receptor activation leads to:

• Enhanced cortical plasticity — 5-HT2A activation promotes dendritic spine growth and synaptogenesis
• Altered network connectivity — Restructuring of brain network patterns associated with depression
• Reduced amygdala reactivity — Decreased threat processing and emotional reactivity

Default Mode Network Modulation

The default mode network (DMN) is hyperactive in depression and anxiety states. Psilocybin has been shown to:

• Temporarily disrupt DMN connectivity — Allowing for new patterns of thought and emotional processing
• Increase global brain connectivity — Enabling novel integrations of emotional experience
• Promote "network reset" — Long-lasting changes in brain network organization

Neuroplasticity Effects

Research has demonstrated that psilocybin promotes neuroplasticity through:

• Increased dendritic spine density in prefrontal cortex neurons
• Enhanced expression of brain-derived neurotrophic factor (BDNF)
• Improved functional connectivity between frontal and limbic regions
• Anti-inflammatory effects potentially relevant to PD neuropathology

Depression in Parkinson's Disease

Prevalence and Impact

Depression is the most common neuropsychiatric complication in PD:

• Affects 30-50% of all PD patients
• Can precede motor symptoms by years
• Significantly impacts quality of life
• Associated with faster disease progression
• Increases caregiver burden and disability

Challenges with Current Treatments

Standard antidepressants face limitations in PD:

| Treatment | Limitations in PD |
|-----------|-------------------|
| SSRIs | May worsen motor symptoms; delayed onset |
| SNRIs | Similar limitations; side effect burden |
| TCAs | Anticholinergic effects; cardiac toxicity |
| Dopamine agonists | May cause impulse control disorders |

Why Psilocybin May Help

Psilocybin offers several potential advantages for PD depression:

Study Design

Intervention Protocol

The trial employs a rigorous design:

• Randomized, double-blind, placebo-controlled structure
• Single or dual psilocybin administrations in a supportive setting
• Integration sessions with trained therapists before and after psilocybin exposure
• Follow-up period to assess durability of effects

Therapeutic Framework

Psychedelic-assisted therapy combines:

Safety Considerations

Key safety measures for PD patients:

• Careful cardiac monitoring (PD patients may have autonomic dysfunction)
• Exclusion of patients with psychosis history (risk of PD psychosis)
• Monitoring for drug interactions with PD medications
• Assessment of impulse control behaviors

Outcome Measures

Primary Endpoints

| Measure | Description |
|---------|-------------|
| Change in depression scores | Assessed using validated scales (e.g., BDI, MADRS) |
| Response rate | Percentage achieving clinically significant improvement |
| Remission rate | Proportion achieving symptom remission |

Secondary Endpoints

| Measure | Description |
|---------|-------------|
| Motor symptom stability | UPDRS motor scores to ensure no worsening |
| Quality of life | PDQ-39 and general quality of life measures |
| Anxiety symptoms | GAD-7 or similar |
| Cognitive function | MoCA and neuropsychological testing |
| Sleep quality | PDSS and general sleep scales |
| Duration of effect | Long-term follow-up of antidepressant response |

Clinical Significance

This trial represents several important firsts:

Broader Implications

If successful, this trial could:

• Establish psilocybin as a treatment option for PD depression
• Encourage research into other psychedelic compounds for neurodegenerative diseases
• Highlight the importance of treating non-motor symptoms in PD
• Advance understanding of the gut-brain axis and serotonin in PD

Serotonin Dysfunction in PD

Parkinson's Disease involves multiple neurotransmitter systems beyond dopamine:

• Serotonin neuron loss — 5-HT neurons in the raphe nuclei are affected in PD
• Reduced serotonin transmission — Contributes to depression and anxiety
• 5-HT2A receptor changes — Altered receptor expression in PD brains
• Connection to Lewy bodies — Serotonergic neurons may contain alpha-synuclein inclusions

Neuroinflammation Connection

PD involves chronic neuroinflammation, and psilocybin may address this through:

• 5-HT2A-mediated anti-inflammatory effects in glial cells
• Modulation of microglial activation
• Reduced pro-inflammatory cytokine production
• Potential disease-modifying implications
• [Parkinson's Disease](/genes/ar)
• [Depression in Neurodegeneration](/diseases/neurodegeneration)
• [Serotonin Signaling](/mechanisms/serotonin-signaling)
• Non-Motor Symptoms in PD
• 5-HT2A Receptor
• [Dorsal Raphe Nuclei](/cell-types/dorsal-raphe)
• [Psychedelics in Neurology](/genes/cs)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein)
• [BDNF Therapy](/therapeutics/bdnf-therapy)

Mechanism of Action

5-HT2A Receptor Agonism

Psilocybin's therapeutic effects in depression are primarily mediated through its activation of serotonin 5-HT2A receptors[@nichols2016]. Upon ingestion, psilocybin is converted to psilocin, which exhibits high affinity for 5-HT2A receptors as a partial agonist[@rickli2016]. This activation leads to downstream effects including:

• Increased glutamate release in prefrontal cortex[@halberstadt2011]
• Enhanced neuroplasticity through BDNF signaling[@ly2018]
• Reduced default mode network (DMN) activity[@carhartharris2014]
• Altered emotional processing networks[@kraehenmann2015]

Relevance to Parkinson's Disease Depression

Depression in PD is thought to involve both dopaminergic and serotonergic dysfunction[@burn2012]. While PD primarily affects dopaminergic neurons in the substantia nigra, serotonergic systems are also compromised, particularly in advanced disease[@politis2015]. The 5-HT2A receptor-mediated effects of psilocybin may address this serotonergic deficit while also promoting neural plasticity that could benefit motor and non-motor symptoms[@froland2022].

Trial Design

Study Population

The trial targets patients with:

• Confirmed Parkinson's Disease diagnosis
• Clinically significant depression (typically HAM-D score ≥ 17)
• Stable PD medication regimen
• No history of psychosis

Treatment Approach

Psilocybin therapy for depression in PD typically involves[@carhartharris2016]:

• Low to moderate doses (10-25mg psilocybin)
• Supportive therapeutic setting with trained facilitators
• Integration sessions following the psychedelic experience
• Multiple treatment sessions over several weeks

Potential Benefits and Risks

Benefits

Psilocybin-assisted therapy has shown promise for treatment-resistant depression in general populations[@griffiths2016]. Potential benefits for PD patients include:

• Rapid-onset antidepressant effects
• Long-lasting benefits from single or few treatments
• Potential improvement in both mood and motor symptoms
• Addressing depression that responds poorly to conventional antidepressants

Risks and Considerations

Safety considerations include[@johnson2016]:

• Potential for transient anxiety or confusion during treatment
• Risk of psychosis in susceptible individuals
• Possible interactions with PD medications
• Need for careful screening and medical supervision

Connection to Non-Motor Symptoms

Depression in PD significantly impacts quality of life and may accelerate disease progression[@schapira2017]. Treating depression may also improve:

• Cognitive function
• Sleep quality
• Motor symptom perception
• Caregiver burden

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References